Clinical Development & Clinical Trials
We are committed to rigorous investigation of our innovations. In the last decade (2008-2017) we have conducted or sponsored close to 1300 clinical studies involving around 530,000 patients, including large outcomes trials such as EMPA-REG that explored cardiovascular outcomes in type 2 diabetes.
With significant experience in large outcome trials, we have the expert resources to inform the planning, design and conduct of clinical studies; study the use, safety and effectiveness of treatments in large populations; and determine the benefit-risk profiles of treatments. In addition, our large and experienced global team can be mobilized to respond to evolving regulatory requirements.
Clinical phase projects can also benefit from Boehringer Ingelheim’s dedicated phase I site that is part of our translational research organization.
We are committed to presenting our data at world-leading congresses and publishing in quality, peer-reviewed journals with a high impact factor.